Mexico approves the 1mg/vial presentation of EGRIFTA® (tesamorelin for injection)

Mar 08, 2016
PDF Version
Supporting Materials:

Theratechnologies Inc. (Theratechnologies) (TSX: TH) is pleased to announce that COFEPRIS, Mexico’s health agency, has approved the 1mg/vial presentation of tesamorelin for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy allowing the commercialization of EGRIFTA® in this territory.